Chipscreen Biosciences Announces NMPA IND Approval for NW001, a PD-L1-Targeted Epigenetic Immune-Modulating Antibody Conjugate

Posted on by sHq_LoGiNz

SHENZHEN, China–(BUSINESS WIRE)– #ChipscreenBiosciences–The Phase 1 trial will assess the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NW001 in patients with advanced tumors.

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.